In research published in Developmental Medicine & Child Neurology, investigators developed a brief, reliable, and valid screening tool to help identify individuals with Duchenne muscular dystrophy (a neuromuscular disorder) who are at increased risk of brain-related comorbidities, such as language disorders, attention-deficit/hyperactivity disorder, and anxiety.
The research team developed the questionnaire-based screening tool, called the BIND (Brain Involvement iN Dystrophinopathies) screener, by reviewing the medical literature and incorporating expert consensus, and translated it into 11 languages. The questionnaire asks parents, caregivers, or patients to rate the impact of 18 cognitive, behavioral, and emotional items.
The BIND screener demonstrated strong accuracy in identifying individuals with Duchenne muscular dystrophy who had previously been diagnosed with neurodevelopmental or psychiatric conditions in an international sample of 835 participants. Additional validation was conducted in a subsample of 90 children and adolescents who underwent in-depth cognitive and clinical assessments.
“Families often tell us that cognitive and behavioral difficulties can be as challenging as the physical symptoms of Duchenne. This screener is designed to help identify those concerns earlier, so that children and adults can be referred for appropriate support,” said corresponding author Rubén Miranda, PhD, of Universidad Complutense de Madrid, Spain.
URL: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.70145
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
Developmental Medicine & Child Neurology (DMCN) is a multidisciplinary journal that has defined the fields of paediatric neurology and childhood-onset neurodisability for over 60 years. DMCN disseminates the latest clinical research results globally to enhance the care and improve the lives of disabled children and their families.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.